Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.
mTOR inhibitors avoid calcineurin nephrotoxicity, but sirolimus de novo is associated with unacceptable side effects and higher rejection rates. We have investigated a modified strategy: alemtuzumab induction with tacrolimus and mycophenolate maintenance, switching from tacrolimus to sirolimus at 6...
Hlavní autoři: | Sutherland, A, Akhtar, M, Zilvetti, M, Brockmann, J, Ruse, S, Fuggle, S, Sinha, S, Harden, P, Friend, P |
---|---|
Médium: | Conference item |
Vydáno: |
2014
|
Podobné jednotky
-
Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.
Autor: Flechner, S, a další
Vydáno: (2005) -
Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.
Autor: Trzonkowski, P, a další
Vydáno: (2008) -
ALEMTUZUMAB INDUCTION IN PANCREAS TRANSPLANTATION
Autor: Muthusamy, A, a další
Vydáno: (2011) -
Systematic reviews of alemtuzumab in renal transplantation.
Autor: O'Callaghan, J, a další
Vydáno: (2013) -
Systematic reviews of alemtuzumab in renal transplantation
Autor: O'Callaghan, J, a další
Vydáno: (2013)